Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026
CAMBRIDGE, Mass., Oct. 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative AI–driven drug discovery company, today announced promising first-in-human Phase 1 data for ISM6331, its investigational oral pan-TEAD inhibitor designed using Chemistry42 generative AI platform. Among response-evaluable participants with mesothelioma, the results showed a 40.0% objective response rate (ORR) at 130 mg once daily and an 18.2% ORR with a 68.2% disease control rate (DCR) across the dose cohorts.
Findings were presented as a Rapid Oral at the European Society…
Read the full report on Pr Newswire Apac
Story file
- Section
- Health
- Topics
- Startups, AI & gadgets, Farmers & agriculture, Health alerts
- First reported by
- Pr Newswire Apac
- Reporter
- cision pr newswire
- Published
- Monday, 26 October 2026, 6:30 pm IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Pr Newswire Apac with a short summary and a link to the original. The original reporting belongs to the publisher. Spotted an error in our summary? Tell our corrections desk.
